Search

Additional file 2: Supplemental Figure 1. Residual plasma correction. (a-c) Levels of a vascular marker (infliximab) in serum (a) and tissues (b) were used to infer residual plasma contamination and calculate correction factors (c). Also shown is the plasma volume fraction derived from the data in (Shah and Betts 2012). (d) Relative contribution of the residual plasma fraction to the total tissue AUC in tumor-bearing Balb/c nude mice.

Additional file 4: Supplemental Figure 3. Schematic illustration of the principle of the centrifugation method to obtain interstitial fluid.

Additional file 1: Supplemental Table 1. Serum pharmacokinetic parameters in non-tumor bearing mice for charge-patch antibody variants as obtained by noncompartmental analysis.

Additional file 3: Supplemental Figure 2. Interstitial concentrations derived from total tissue levels in tumor-bearing Balb/c nude mice using the method of Chang et al. (Chang et al. 2020) suggest similar delivery to the tumor interstitium, while liver and muscle interstitial levels differ significantly.